Thrivent Financial for Lutherans Purchases 8,552 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Thrivent Financial for Lutherans grew its position in Castle Biosciences, Inc. (NASDAQ:CSTL) by 58.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 23,290 shares of the company’s stock after buying an additional 8,552 shares during the period. Thrivent Financial for Lutherans owned 0.08% of Castle Biosciences worth $664,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. GSA Capital Partners LLP bought a new stake in shares of Castle Biosciences in the 3rd quarter valued at about $1,478,000. Lisanti Capital Growth LLC boosted its holdings in shares of Castle Biosciences by 60.2% in the 3rd quarter. Lisanti Capital Growth LLC now owns 154,710 shares of the company’s stock valued at $4,412,000 after buying an additional 58,160 shares in the last quarter. Assetmark Inc. boosted its holdings in shares of Castle Biosciences by 16.8% in the 3rd quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock valued at $149,000 after buying an additional 748 shares in the last quarter. Summit Global Investments boosted its holdings in shares of Castle Biosciences by 27.8% in the 3rd quarter. Summit Global Investments now owns 30,441 shares of the company’s stock valued at $868,000 after buying an additional 6,629 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of Castle Biosciences by 2.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock valued at $43,879,000 after buying an additional 40,377 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

CSTL has been the topic of a number of recent analyst reports. Canaccord Genuity Group raised their price target on shares of Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, October 29th. BTIG Research lifted their target price on shares of Castle Biosciences from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Lake Street Capital lifted their target price on shares of Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Scotiabank lifted their target price on shares of Castle Biosciences from $37.00 to $44.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, November 6th. Finally, Robert W. Baird lifted their target price on shares of Castle Biosciences from $37.00 to $39.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $37.88.

Castle Biosciences Stock Performance

CSTL opened at $31.88 on Thursday. Castle Biosciences, Inc. has a 12-month low of $16.97 and a 12-month high of $35.84. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $892.96 million, a PE ratio of 159.41 and a beta of 0.92. The firm has a 50 day moving average of $31.04 and a two-hundred day moving average of $26.84.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.14. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. The company had revenue of $85.78 million during the quarter, compared to analyst estimates of $78.55 million. During the same period last year, the firm posted ($0.26) EPS. On average, analysts anticipate that Castle Biosciences, Inc. will post -0.08 EPS for the current year.

Insider Activity

In other news, insider Tobin W. Juvenal sold 3,507 shares of Castle Biosciences stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $35.56, for a total transaction of $124,708.92. Following the completion of the transaction, the insider now directly owns 54,178 shares of the company’s stock, valued at $1,926,569.68. The trade was a 6.08 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Derek J. Maetzold sold 986 shares of Castle Biosciences stock in a transaction that occurred on Friday, October 4th. The shares were sold at an average price of $28.73, for a total transaction of $28,327.78. Following the transaction, the insider now directly owns 94,622 shares of the company’s stock, valued at approximately $2,718,490.06. This trade represents a 1.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,213 shares of company stock valued at $752,673 in the last three months. 7.20% of the stock is currently owned by corporate insiders.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.